Top Page
Genflow Biosciences Plc
(LSE:GENF)
Genflow Biosciences Plc (GENF) vs. iShares MSCI United Kingdom ETF (EWC)
Genflow Biosciences Plc Business Overview & Revenue Model
Genflow Biosciences Plc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -150.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -150.95K | -1.20K | -1.03K | -130.00 | 0.00 | 0.00 |
| EBITDA | -1.27M | -1.59M | -1.80M | -1.33M | -988.10K | -1.09K |
| Net Income | -1.27M | -1.59M | -1.63M | -1.34M | -988.29K | -651.01K |
Balance Sheet | ||||||
| Total Assets | 468.38K | 385.91K | 1.07M | 2.62M | 276.55K | 283.78K |
| Cash, Cash Equivalents and Short-Term Investments | 279.44K | 278.68K | 683.97K | 2.36M | 224.00K | 254.23K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 771.38K | 788.92K | 345.74K | 250.99K | 221.43K | 64.80K |
| Stockholders Equity | -303.00K | -403.01K | 725.91K | 2.37M | 55.12K | 218.98K |
Cash Flow | ||||||
| Free Cash Flow | -1.28M | -1.08M | -1.66M | -1.37M | -747.38K | -439.46K |
| Operating Cash Flow | -1.28M | -1.08M | -1.66M | -1.37M | -747.38K | -439.46K |
| Investing Cash Flow | 372.00 | 0.00 | -2.44K | -2.48K | 198.50K | 216.55K |
| Financing Cash Flow | 865.22K | 656.63K | 0.00 | 3.50M | 783.71K | 1.96M |
Genflow Biosciences Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | £22.25M | -3.03 | -213.66% | ― | 39.88% | 81.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £1.29M | -0.72 | -89.43% | ― | 44.32% | 60.00% | |
47 Neutral | £10.58M | -1.89 | 377.33% | ― | ― | ― | |
45 Neutral | £10.38M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
44 Neutral | £15.63M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
41 Neutral | £80.52M | -4.89 | -63.53% | ― | 198.49% | -26.66% |
Genflow Biosciences Plc Corporate Events
Genflow Biosciences has raised £800,000 through a subscription of 42,105,263 new ordinary shares at 1.9p each, with one warrant attached per share, to fund the advancement of its scientific programs and extend its cash runway. The financing, which included participation from CEO Eric Leire and newly appointed chairman Gad Berdugo, is intended to strengthen the company’s balance sheet and support forthcoming licensing negotiations, while increasing the company’s issued share capital to 535,653,205 shares upon admission of the new stock to trading.
Subscribers received two-year warrants exercisable at the issue price, which, if fully exercised, could raise a further £800,000 and lead to the issuance of an additional 42,105,263 shares. The transaction underscores insider confidence in Genflow’s strategy as it progresses its gene therapy pipeline for age-related conditions, and the enlarged share base will form the new reference point for investors monitoring significant holdings under UK disclosure rules.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Genflow Biosciences Plc, a UK-based longevity-focused biotechnology company listed in London and on OTCQB, is developing gene therapies such as its lead candidate GF-1002, which targets aging-related conditions and is under evaluation in an aged-dog study and in upcoming trials for MASH. The company aims to extend healthy lifespan and address the growing burden of age-related disease globally.
Genflow announced that shareholders approved all resolutions at its latest General Meeting, including authority for directors to allot securities and to disapply statutory pre-emption rights, both backed by strong voting majorities. The outcome gives the company greater flexibility to issue new equity, potentially supporting future financing and strategic initiatives as it advances its gene therapy pipeline in the competitive longevity biotech space.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Genflow Biosciences Plc, a longevity-focused gene therapy developer based in the UK with Belgian R&D operations, is advancing its lead asset GF-1002, which targets age-related decline via a centenarian SIRT6 variant and is under evaluation in canine sarcopenia and longevity studies, alongside a planned clinical programme in MASH. The company has received the first €336,467 tranche of a €4 million non-dilutive grant from Belgium’s Wallonia Region, providing three-year funding aligned with its GF-1002 MASH roadmap and strengthening its financial capacity to pursue key development milestones and sustain progress on its lead programme.
The initial grant disbursement, which will be used for eligible project activities, is the first of several milestone-based instalments expected over the programme’s duration. This regional support underpins Genflow’s positioning in the competitive longevity and metabolic liver disease fields by offering non-dilutive capital, thereby limiting shareholder dilution while potentially accelerating the gene therapy’s path through development and enhancing visibility among investors and partners.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Genflow Biosciences has reported positive preliminary interim results from its SLAB clinical trial testing its proprietary SIRT6 centenarian gene therapy in 24 aged beagle dogs. The randomized, blinded study found that all treatment groups showed better survival than controls during the dosing period, with no adverse events and an encouraging safety and tolerability profile in older companion animals.
Dogs receiving the gene therapy also showed improvements versus controls in quality of life, muscle mass preservation, frailty index, and coat condition, countering typical age-related decline. Key biological endpoints, including methylation clock-based biological age and muscle biopsy histology, are still being analysed, and the company expects full data within about two months to support ongoing discussions with potential animal health partners.
Genflow believes the consistent positive signals across survival and functional measures strengthen the case for its SIRT6 platform as a first-in-class approach to addressing age-related decline in companion animals. The company is proceeding with a follow-up phase to assess durability of benefits and age-related disease onset, using the emerging dataset to advance potential licensing, co-development, and commercialisation deals in the companion animal market.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Genflow Biosciences plans to seek shareholder approval at a 2 March 2026 general meeting to authorize the issue of up to 188,947,368 new ordinary shares, equivalent to about 38% of its current share capital. The authority would allow the board to undertake a potential non-pre-emptive equity raise via shares or warrants, giving directors flexibility over pricing, allocation, and investor selection.
The company has not yet secured investors or set terms, and there is no certainty the fundraising will proceed, but any proceeds would be directed toward advancing its MASH gene therapy program to IND-enabling stage, completing payments and licensing efforts for its aged-dog clinical trial, glaucoma proof-of-concept and business development work, and key EU and U.S. patent processes. The move underscores Genflow’s need for fresh capital to progress its pipeline and intellectual property portfolio, which could be significant for its positioning in the emerging longevity and age-related therapeutics market.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Genflow Biosciences has received administrative approval for approximately €4 million in non-dilutive funding support from Belgium’s Wallonia region to advance its lead gene therapy, GF-1002, for the treatment of MASH, with the three-year support package expected to begin disbursement by May 2026 and to cover eligible project expenses incurred from 2025. For 2026, the company is prioritising capital-efficient pipeline development and early-stage collaborations, highlighting upcoming data from its dog ageing study GF-1004, progress in glaucoma delivery optimisation through LNP and CRO partnerships, and continued work on sarcopenia and its ExoFastTrack platform, all aimed at strengthening its ageing-focused gene therapy pipeline and enhancing prospects for future partner engagement and shareholder value.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Genflow Biosciences has appointed Gad Berdugo as Independent Non-Executive Chairman, a move aimed at accelerating the company’s corporate development and R&D strategy as it advances its gene-therapy programs for age-related diseases. Berdugo’s three decades of experience in global biotech business development, U.S. capital markets and RNA-based therapeutics, including lipid nanoparticle delivery, are expected to strengthen Genflow’s scientific platform, expand its U.S. and global presence, and support the company as it enters a new development phase with key data readouts and a sharpened focus on high-potential programs, while existing director Tamara Joseph remains on the board to ensure governance continuity.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Genflow Biosciences reported a year of scientific and clinical progress in 2025, highlighting completion of dosing in its blinded SIRT6-based gene therapy trial in aging dogs without observed adverse events, with initial efficacy data expected in the first quarter of 2026 and longer-term results by mid-year. The company advanced its MASH program by repositioning GF-1002 toward patients with advanced fibrosis, generating new preclinical proof-of-concept data on hepatocellular carcinoma prevention, and exploring mRNA/LNP delivery to enable repeat dosing and reduce costs, while also entering ophthalmology with a glaucoma program aimed at neuroprotection of retinal ganglion cells in a market forecast to reach up to $14 billion in the early 2030s. Additional efforts included steady progress in a sarcopenia program and the ExoFastTrack initiative, both supporting the broader pipeline. Looking to 2026, Genflow plans to rationalize its portfolio around the most promising, partner-attractive assets and pursue early-stage licensing and collaboration deals to secure non-dilutive funding, strengthen its partner ecosystem, and support its transition into a more mature, growth-oriented phase with multiple upcoming data readouts and a growing intellectual property base.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.